WO1990013216A2 - Inflammatory disease treatment - Google Patents
Inflammatory disease treatment Download PDFInfo
- Publication number
- WO1990013216A2 WO1990013216A2 PCT/US1990/002045 US9002045W WO9013216A2 WO 1990013216 A2 WO1990013216 A2 WO 1990013216A2 US 9002045 W US9002045 W US 9002045W WO 9013216 A2 WO9013216 A2 WO 9013216A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alcohols
- compositions
- triacontanol
- chain
- hexacosanol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- INFLAMMATORY DISEASE TREATMENT Field of the Invention This invention relates to alcohol-containing compositions which are useful in treating various virus infections and inflammatory diseases of the skin and membranes, including burns, laceration damage and acute injuries. More specifically the present invention relates to a narrow class of aliphatic straight-chain saturated monohydric alcohols which have from 20 to 26, preferably 22 to 26, carbons in the chain.
- Triacontanol has also been reported to accelerate the decomposition of sewage and reduce H 2 S, Starr, Jerry, U.S. Patent 4,246,100.
- Beeswax comprises, inter alia, esters of long-chain aliphatic alcohols having chain lengths in the area of interest, and it is known to obtain such alcohols by hydrolysis of beeswax.
- Beeswax has been used since antiquity in a great variety of cosmetic and therapeutic applications, as a base for lipstick, in lotions and creams, as an emollient and as a constituent in therapeutic products for topical and membrane application.
- Various constituents of beeswax and products derived from beeswax have also been used in cosmetic and therapeutic applications. For example, Slimak, Karen M., U.S. Patent No.4,793,991, describes a hypoallerginic cosmetic comprising single plant source beeswax.
- composition intended for topical application comprising a major portion liquified gaseous propellant and a minor portion of a mixture of C-12 to C-30 fatty alcohols which were used simply to mark the areas of application of the aerosol is contained in U.S. Patent 3,584,115 to Gebhart.
- Clark, U.S. Patent 4,670,471 discloses the use of triacontanol, in a suitable carrier, as a treatment for inflammatory disorders such as herpes simplex, eczema, shingles, atopic dermatitis, psoriasis, etc. Clark performed experiments with the compositions of the type disclosed by Gebhart, U.S. Patent 3,584,115 comprising an aerosol and a mixture of triacontanol and palmitic acid, which Clark indicates to be as effective as pure triacontanol, and concluded that the aerosol carrier destroyed the effect of triacontanol and that a hydrophilic carrier for triacontanol was necessary to achieve the desired anti-inflammatory effect.
- Clark's composition was simply saponified beeswax which would contain triacontanol and palmitic acid, as Clark indicates, but which would also contain, as substantial constituents, hexacosanolic acid and various hydrocarbons.
- Results gas chromatographic-mass spectrum analysis of various compositions believed to have been used by Clark were not definitive, but suggested that at least some such compositions were very complex mixtures, some of which may be lower alkanes, esters, acids or alcohols. Whether or not these were found by Clark to be effective anti-inflammatory compositions is not known.
- Patent 3,863,633 disclose a composition for topical treatment of the eye which comprises a lipophilic substance, a hydrophilic swellable polymer and from 10 to 80 percent C-12 to C-22 surface active alcohols such as 1-docosanol, 1-hexadecanol, 1-octadecanol and 1-eicosanol which serve as a stabilizer for the mixture.
- Short-chain alcohols i.e. under about 16 carbons
- longer chain alcohols particularly the aliphatic alcohols tend to be non-irritating
- 1-Triacontanol a 30-carbon unsaturated aliphatic alcohol, in a suitable hydrophilic carrier has (or may have depending upon the precise compositions used by Clark) value in treating inflammatory conditions of the skin (Clark, supra).
- Shorter chain C-10 to C-14 aliphatic alcohols demonstrate low level in vitro virucidal characteristics, while C-18 alcohols show no discemable virucidal activity in vitro (Snipes, supra).
- Polyunsaturated C-20 to C-24 alcohols inactivate enveloped virus (Revici et al., supra).
- C-16 to C-24 aliphatic alcohols are useful as stabilizers in carrier compositions for drugs having diverse physiological activity.
- the present invention comprises compositions and methods for topical treatment of inflammatory diseases, including virus-induced inflammation, burns, laceration damage and acute injuries, in which the active constitute consists essentially of C-20 to C-26, and preferably C-22 to C-26 aliphatic alcohols, e.g. docosanol, tetracosanol and hexacosanol.
- the present invention is embodied in a method treating inflammatory and viral skin diseases, such as may result, for example, from virus infection, burns, lacerations and acute injuries, comprising application of a composition consisting of one or more of C-20 to C-26 aliphatic alcohols, preferably one or more alcohols selected from the group consisting of 1 -docosanol, 1 -tetracosanol and 1- hexacosanol, in a physiologically compatible carrier.
- compositions suitable for use in this invention consists essentially of a carrier which is physiologically compatible with the skin and membrane tissues of the patient, i.e. non-irritating, and which is substantially inactive physiologically (except for possible emollient properties) and, as the physiologically active composition, one or more C-20 to C-26 aliphatic alcohols, e.g. one or more of 1- eiconol, 1-docosanol, 1 -tetracosanol and 1-hexacosanol.
- the method may be carried out using compositions in which the sole physiologically active agent(s) is the C-20 to C-26 aliphatic alcohol, or comparable compositions which may also include other physiologically active constituents which do not interfere with the efficacy of the C-20 to C-26 alcohols.
- composition of the carrier is not critical so long as the carrier is non- irritating to skin and membranes and is substantially free from physiological effect, e.g. has no physiological effect other than be an emollient.
- compositions for use in this invention would be similar to that disclosed by Katz, et al. in U.S. Patent 3,592,930 without the addition of any other physiologically active constituent, e.g. a mixture of C-20 to C-26 alcohols, preferably one or more of the alcohols 1-docosanol, 1 -tetracosanol and 1- hexacosanol, a glycol solvent such as propylene glycol, and, if desired, a plasticizer such as glycerol or a polyethylene glycol having a molecular weight of from 800 to 20,000.
- physiologically active constituent e.g. a mixture of C-20 to C-26 alcohols, preferably one or more of the alcohols 1-docosanol, 1 -tetracosanol and 1- hexacosanol, a glycol solvent such as propylene glycol, and, if desired, a plasticizer such as glycerol or a polyethylene glycol having
- a suitable carrier may comprise white petrolatum, stearyl alcohol, isopropyl myristate, sorbitan monooleate, propylene glycol, water and a detergent such as polyoxyl stearate mixed to form a stable cream.
- the active alcohols e.g. one or more of 1-docosanol, 1 -tetracosanol and 1-hexacosanol is added to the carrier in amounts from about 0.1 to about 25 percent by weight, typically in the range of from 1 to 5 percent. Higher concentrations of the active alcohol(s) may be used but no increase in efficacy results from concentrations above about 15 to 25 weight percent.
- the concentration of the active alcohol(s) is not critical, but optimum efficacy coupled with efficient use of the active ingredient would be found in the 1 to 5 weight percent range.
- compositions for use in the method of this invention would be a cream formulated of water, white petrolatum, isopropyl myristate, lanolin alcohols, mineral oil and cetylstearyl alcohol into which from 1 to 5 percent of C- 20 to C-26 alcohols, e.g. one or more alcohols selected from the group consisting of 1-docosanol, 1-tetracosanol and 1-hexacosanol has been intimately mixed.
- An alternative suitable composition for use in this invention may be formulated of stearyl alcohol, petrolatum, water and mineral oil stabilized with a detergent such as sodium lauryl sulfate and may include a preservative such as methylparaben or propylparaben, and an effective amount, typically from about 0.1 to 5 percent by weight of one or more alcohols selected from the group consisting of 1-docosanol, 1-tetracosanol and 1-hexacosanol.
- suitable preservatives such as ethylene diamine tetraacetate salts, methylparaben, propylparaben, etc.
- suitable preservatives such as ethylene diamine tetraacetate salts, methylparaben, propylparaben, etc.
- Penetrants such as azone, may also be added if desired.
- the method of the present invention will require application to the inflamed area of skin or membrane of compositions, such as those described above as merely exemplary, in which the active ingredient consists essentially of one or more aliphatic alcohols having from 20 to 26 carbons in the aliphatic chain, an exemplary composition comprising one or more alcohols selected from the group consisting of 1-docosanol, 1-tetracosanol and 1-hexacosanol.
- Three to 6 applications of the ointment or cream per day will, in most cases, be expected to produce prompt relief from the itching, discomfort associated with such diseases and promote healing of damaged tissues within a few days to a few weeks.
- compositions useful in the present method is one or more aliphatic alcohols having from 20 to 26 carbons in the aliphatic chain of the alcohol(s), and that the composition of the carrier is non-critical and subject to great variation.
- This invention is useful in treating vims-induced inflammatory diseases of humans and other animals, and inflammation resulting from bums, lacerations and acute injuries.
Abstract
A method treating virus-induced and inflammatory diseases of skin and membranes in humans or animals, comprising application of a composition consisting of one or more of the aliphatic alcohols docosanol, tetracosanol and hexacosanol in a physiologically compatible carrier is disclosed.
Description
INFLAMMATORY DISEASE TREATMENT Field of the Invention This invention relates to alcohol-containing compositions which are useful in treating various virus infections and inflammatory diseases of the skin and membranes, including burns, laceration damage and acute injuries. More specifically the present invention relates to a narrow class of aliphatic straight-chain saturated monohydric alcohols which have from 20 to 26, preferably 22 to 26, carbons in the chain.
Background of the Invention It is well-known that certain selected alcohols have some physiological activity. It is known, for example, that 1-triacontanol stimulates the growth of plants, see, e.g. Ries, Stanley K. and Sweeney, Charles C, U.S. Patent 4,150,970. Interestingly, the C-30 alcohol triacontanol appears to possess this physiological activity and that the C-28 and C-32 do not possess such physiological activity, or at least have very much less physiological activity in plant growth, see, e.g., the patents and publications of Ries et al. , ibid, and of Ashmead, Harvey H. , Weleber, Andrew J., Laughlin, Robert G., Nickey, Donald O. & Parker, Dane. K, and Ohorogge, Alvin J.
Triacontanol has also been reported to accelerate the decomposition of sewage and reduce H2S, Starr, Jerry, U.S. Patent 4,246,100.
Beeswax comprises, inter alia, esters of long-chain aliphatic alcohols having chain lengths in the area of interest, and it is known to obtain such alcohols by hydrolysis of beeswax. Beeswax has been used since antiquity in a great variety of cosmetic and therapeutic applications, as a base for lipstick, in lotions and creams, as an emollient and as a constituent in therapeutic products for topical and membrane application. Various constituents of beeswax and products derived from beeswax have also been used in cosmetic and therapeutic applications. For example, Slimak, Karen M., U.S. Patent No.4,793,991, describes a hypoallerginic cosmetic comprising single plant source beeswax. Gans, Eugen, Nacht, Sergio and Yeung, David have described the use of the non-polar saturated straight chain C-21
to C-33 hydrocarbon fraction of beeswax in the treatment of inflammatory skin disorders, U.S. Patent No. 4,623,667.
The mechanism of the rather diverse and unpredictable physiological effects of the various alcohols are, at best, poorly understood and studies are not generally definitive. There appears to some interaction of certain n-alkanols with lipid bilayer membranes, Westerman, PW, Pope, JM, Phonphok, N., Dan, JW, dubro, DW, Biochim Biophys ActaQ^THERLANDS) 939, 64-78 (1988), and studies have been conducted respecting the partitioning of long-chain alcohols into lipid bilayers, Franks NP & Lieb WR, Proc. Natl Acad. Sci. USA 835116-20 (1986); cholesterol solubility of n-alkanols, Pal S. & Moulik SP, Indian J Biochem Biophys 24 24-8
(1987); neurological effects of certain long-chain alcohols, Natarajan V & Schmid
HH, Lipids 12 128-30 (1977); Snider SR, Ann Neurol 16 723 (1984); Borg J,
Toazara J, Hietter H, Henry M, Schmitt G, Luu B, FEBS Lett 213 406-10 (1987).
Levin, Ezra reported that tetracosanol, hexacosanol, octacosanol and triacontanol and their esters improved physical performance of athletes and disclosed compositions comprising such alcohols and esters in vegetable oil bases for oral ingestion, U.S. Patent 3,031,376.
An incidental disclosure of a composition intended for topical application comprising a major portion liquified gaseous propellant and a minor portion of a mixture of C-12 to C-30 fatty alcohols which were used simply to mark the areas of application of the aerosol is contained in U.S. Patent 3,584,115 to Gebhart.
Clark, U.S. Patent 4,670,471 discloses the use of triacontanol, in a suitable carrier, as a treatment for inflammatory disorders such as herpes simplex, eczema, shingles, atopic dermatitis, psoriasis, etc. Clark performed experiments with the compositions of the type disclosed by Gebhart, U.S. Patent 3,584,115 comprising an aerosol and a mixture of triacontanol and palmitic acid, which Clark indicates to be as effective as pure triacontanol, and concluded that the aerosol carrier destroyed the effect of triacontanol and that a hydrophilic carrier for triacontanol was necessary to achieve the desired anti-inflammatory effect. There is some reason to believe that Clark's composition was simply saponified beeswax which would contain triacontanol and palmitic acid, as Clark indicates, but which would
also contain, as substantial constituents, hexacosanolic acid and various hydrocarbons. Results gas chromatographic-mass spectrum analysis of various compositions believed to have been used by Clark were not definitive, but suggested that at least some such compositions were very complex mixtures, some of which may be lower alkanes, esters, acids or alcohols. Whether or not these were found by Clark to be effective anti-inflammatory compositions is not known. McKeough, Mark & Spruance, SL evaluated the efficacy of 5 percent triacontanol in a branch chain ester base in the treatment of HSV-1 dorsal cutaneous infection in guinea pigs and concluded that the active ingredient in triacontanol is the long chain hydrocarbon (unpublished report in the file of US Patent 4,670,471).
Revici, Emanuel, Sherwood, Bob E., Benecke, Herman P., Rice, John M., and Geisler, Richard W., US Patent 4,513,008, disclose a method of inactivating enveloped virus using C-20 to C-24 polyunsaturated acids, aldehydes or alcohols having 5-7 double bonds, and references disclosures by Sands et al. (Antimicrobial Agents and Chemotherapy 15, 67-73 (1979)), antiviral activity of C-14 to C-20 unsaturated alcohols having 1-4 double bonds, C-20 tetraenyl alcohol having low activity, Snipes et al., (Antimicrobial Agents and Chemotherapy 11, 98-104 (1977) and Symp. Pharm. Effects Lipids (AOCS Monograph No. 5) 63-74 (1978)) even lower antiviral activity for saturated long-chain alcohols. Katz, Martin & Neiman, Herbert M, U.S. Patent 3,592,930 disclose a medicant vehicle containing from 15 to 45 parts of saturated fatty alcohol from 16 to 24 carbons, along with glycol solvent, plasticizer, penetrant and adjuvant which is used as a carrier for antibiotics, steroids, antihistamines, etc. Ryde, Emma Marta & Ekstedt, Jan Erik, U.S. Patent 3,863,633 disclose a composition for topical treatment of the eye which comprises a lipophilic substance, a hydrophilic swellable polymer and from 10 to 80 percent C-12 to C-22 surface active alcohols such as 1-docosanol, 1-hexadecanol, 1-octadecanol and 1-eicosanol which serve as a stabilizer for the mixture.
The content of the prior art and the corresponding skill of the art, relative to topically administered compositions, may be summarized as follows: Short-chain alcohols, i.e. under about 16 carbons, tend to be irritants while longer chain
alcohols, particularly the aliphatic alcohols tend to be non-irritating (Katz et al., supra). 1-Triacontanol, a 30-carbon unsaturated aliphatic alcohol, in a suitable hydrophilic carrier has (or may have depending upon the precise compositions used by Clark) value in treating inflammatory conditions of the skin (Clark, supra). Shorter chain C-10 to C-14 aliphatic alcohols demonstrate low level in vitro virucidal characteristics, while C-18 alcohols show no discemable virucidal activity in vitro (Snipes, supra). Polyunsaturated C-20 to C-24 alcohols inactivate enveloped virus (Revici et al., supra). C-16 to C-24 aliphatic alcohols are useful as stabilizers in carrier compositions for drugs having diverse physiological activity. Respecting aliphatic alcohols, one would predict from the studies of Snipes and Clark that, in the continuum of aliphatic alcohols from C-10 to C-30 virucidal activity, at a very low level, may appear (if in vitro studies may be used to predict in vivo results) in C-10 to C-14 alcohols (which would also be irritants as reported by Katz), that virucidal activity disappears in the C-16 to C-28 range and then appears uniquely (if Clark's compositions were pure triacontanol or mixtures of triacontanol with palmitic acid as he indicates) with the C-30 alcohol 1-triacontanol, which has been shown to have unique physiological effects in plant treatment.
Even considering the possible ambiguity of Clark's compositions, one would not predict any significant virucidal activity for aliphatic alcohols in the C-20 through C-28 chain-length.
Notwithstanding the negative teachings of the prior art, the present invention comprises compositions and methods for topical treatment of inflammatory diseases, including virus-induced inflammation, burns, laceration damage and acute injuries, in which the active constitute consists essentially of C-20 to C-26, and preferably C-22 to C-26 aliphatic alcohols, e.g. docosanol, tetracosanol and hexacosanol.
Summary of the Invention The present invention is embodied in a method treating inflammatory and viral skin diseases, such as may result, for example, from virus infection, burns, lacerations and acute injuries, comprising application of a composition consisting of one or more of C-20 to C-26 aliphatic alcohols, preferably one or more alcohols
selected from the group consisting of 1 -docosanol, 1 -tetracosanol and 1- hexacosanol, in a physiologically compatible carrier.
Description of the Preferred Embodiments The compositions suitable for use in this invention consists essentially of a carrier which is physiologically compatible with the skin and membrane tissues of the patient, i.e. non-irritating, and which is substantially inactive physiologically (except for possible emollient properties) and, as the physiologically active composition, one or more C-20 to C-26 aliphatic alcohols, e.g. one or more of 1- eiconol, 1-docosanol, 1 -tetracosanol and 1-hexacosanol. The method may be carried out using compositions in which the sole physiologically active agent(s) is the C-20 to C-26 aliphatic alcohol, or comparable compositions which may also include other physiologically active constituents which do not interfere with the efficacy of the C-20 to C-26 alcohols.
The composition of the carrier is not critical so long as the carrier is non- irritating to skin and membranes and is substantially free from physiological effect, e.g. has no physiological effect other than be an emollient.
An exemplary composition for use in this invention would be similar to that disclosed by Katz, et al. in U.S. Patent 3,592,930 without the addition of any other physiologically active constituent, e.g. a mixture of C-20 to C-26 alcohols, preferably one or more of the alcohols 1-docosanol, 1 -tetracosanol and 1- hexacosanol, a glycol solvent such as propylene glycol, and, if desired, a plasticizer such as glycerol or a polyethylene glycol having a molecular weight of from 800 to 20,000.
A suitable carrier may comprise white petrolatum, stearyl alcohol, isopropyl myristate, sorbitan monooleate, propylene glycol, water and a detergent such as polyoxyl stearate mixed to form a stable cream. The active alcohols, e.g. one or more of 1-docosanol, 1 -tetracosanol and 1-hexacosanol is added to the carrier in amounts from about 0.1 to about 25 percent by weight, typically in the range of from 1 to 5 percent. Higher concentrations of the active alcohol(s) may be used but no increase in efficacy results from concentrations above about 15 to 25 weight percent. The concentration of the active alcohol(s) is not critical, but optimum
efficacy coupled with efficient use of the active ingredient would be found in the 1 to 5 weight percent range.
Another suitable composition for use in the method of this invention would be a cream formulated of water, white petrolatum, isopropyl myristate, lanolin alcohols, mineral oil and cetylstearyl alcohol into which from 1 to 5 percent of C- 20 to C-26 alcohols, e.g. one or more alcohols selected from the group consisting of 1-docosanol, 1-tetracosanol and 1-hexacosanol has been intimately mixed.
An alternative suitable composition for use in this invention may be formulated of stearyl alcohol, petrolatum, water and mineral oil stabilized with a detergent such as sodium lauryl sulfate and may include a preservative such as methylparaben or propylparaben, and an effective amount, typically from about 0.1 to 5 percent by weight of one or more alcohols selected from the group consisting of 1-docosanol, 1-tetracosanol and 1-hexacosanol.
In all cases, suitable preservatives, such as ethylene diamine tetraacetate salts, methylparaben, propylparaben, etc., may be added to prevent bacterial and fungal growth. Penetrants, such as azone, may also be added if desired.
The method of the present invention will require application to the inflamed area of skin or membrane of compositions, such as those described above as merely exemplary, in which the active ingredient consists essentially of one or more aliphatic alcohols having from 20 to 26 carbons in the aliphatic chain, an exemplary composition comprising one or more alcohols selected from the group consisting of 1-docosanol, 1-tetracosanol and 1-hexacosanol. Three to 6 applications of the ointment or cream per day will, in most cases, be expected to produce prompt relief from the itching, discomfort associated with such diseases and promote healing of damaged tissues within a few days to a few weeks.
The method described is useful in treating a wide variety of viral and inflammatory diseases, examples of which include herpes simplex, eczema, shingles, psoriasis, atopic dermatitis, and in treating inflammation resulting from burns, lacerations and acute injuries. It will be readily understood from the foregoing that the essential constituents) of the compositions useful in the present method is one or more
aliphatic alcohols having from 20 to 26 carbons in the aliphatic chain of the alcohol(s), and that the composition of the carrier is non-critical and subject to great variation.
Industrial Application This invention is useful in treating vims-induced inflammatory diseases of humans and other animals, and inflammation resulting from bums, lacerations and acute injuries.
Claims
1. A method treating vims-induced and inflammatory diseases of skin and membranes in humans or animals, comprising application of a composition consisting of one or more of the aliphatic alcohols docosanol, tetracosanol and hexacosanol in a physiologically compatible carrier.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE122007000080C DE122007000080I2 (en) | 1989-04-28 | 1990-04-16 | USE OF C-22 TO C-26 ALIPHATIC ALCOHOLS FOR THE TREATMENT OF INFLAMMATORY AND VIRAL SKIN DISEASES. |
DE90906552T DE69003652T2 (en) | 1989-04-28 | 1990-04-16 | USE OF C-22 TO C-26 ALIPHATIC ALCOHOLS FOR THE TREATMENT OF FLAMMABLE AND VIRAL SKIN DISEASES. |
AT90906552T ATE95060T1 (en) | 1989-04-28 | 1990-04-16 | USE OF C-22 TO C-26 ALIPHATIC ALCOHOLS IN THE TREATMENT OF INFLAMMATORY AND VIRAL SKIN DISEASES. |
HK120497A HK120497A (en) | 1989-04-28 | 1997-06-26 | Use of C-22 to C-26 aliphatic alcohols in the treatment of inflammatory and viral skin diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/345,084 US4874794A (en) | 1989-04-28 | 1989-04-28 | Inflammatory disease treatment |
US345,084 | 1989-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990013216A2 true WO1990013216A2 (en) | 1990-11-15 |
Family
ID=23353439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/002045 WO1990013216A2 (en) | 1989-04-28 | 1990-04-16 | Inflammatory disease treatment |
Country Status (10)
Country | Link |
---|---|
US (1) | US4874794A (en) |
EP (1) | EP0428642B1 (en) |
JP (1) | JPH03505882A (en) |
AT (1) | ATE95060T1 (en) |
DE (2) | DE69003652T2 (en) |
DK (1) | DK0428642T3 (en) |
ES (1) | ES2060158T3 (en) |
HK (1) | HK120497A (en) |
NL (1) | NL300354I2 (en) |
WO (1) | WO1990013216A2 (en) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5370871A (en) * | 1983-01-24 | 1994-12-06 | The Johns Hopkins University | Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry |
US5380754A (en) * | 1988-02-29 | 1995-01-10 | Virotex Corporation | Topical composition enhancing healing of viral lesions |
US5135956A (en) * | 1988-10-18 | 1992-08-04 | The Regents Of The University Of California | Method of using cytoprotective alcohols to treat neural disease and neural injury |
WO1991005754A2 (en) * | 1989-10-13 | 1991-05-02 | Medafor | Derivatives of long-chain fatty alcohols and their applications, in particular as cytotrophic and cytoprotective molecules, and pharmaceutical compositions containing same |
US5098896A (en) * | 1991-04-23 | 1992-03-24 | Summit Technology, Inc. | Corneal treatment agents |
US5214071A (en) * | 1991-04-23 | 1993-05-25 | Summit Technology, Inc. | Corneal treatment agents |
US5296514A (en) * | 1991-04-23 | 1994-03-22 | Summit Technology, Inc. | Corneal treatment agents |
US5198217A (en) * | 1991-09-24 | 1993-03-30 | Choice Pharmaceuticals | Topical demulcent for viral and inflammatory diseases of the skin |
US5534554A (en) * | 1993-12-13 | 1996-07-09 | Lidak Pharmaceuticals | Sucrose ester-C20 to C28 alcohol formulations |
US6440980B1 (en) * | 1996-09-17 | 2002-08-27 | Avanir Pharmaceuticals | Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs |
US5952392A (en) * | 1996-09-17 | 1999-09-14 | Avanir Pharmaceuticals | Long-chain alcohols, alkanes, fatty acids and amides in the treatment of burns and viral inhibition |
US5948822A (en) | 1996-12-17 | 1999-09-07 | Lidak Pharmaceuticals | Treatment of hyperproliferative skin disorders with C18 to C26 alphatic alcohols |
US20050203187A1 (en) * | 1998-06-01 | 2005-09-15 | Verbiscar Anthony J. | Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof |
NZ506676A (en) | 1999-09-03 | 2002-09-27 | Thomas Harting | Recovery of pure sterols from black liquor soap skimmings or tall oil pitch |
US8173709B2 (en) * | 1999-09-22 | 2012-05-08 | Quadex Pharmaceuticals, Llc | Anti-infective methods for treating pathogen-induced disordered tissues |
PT102410A (en) * | 2000-02-03 | 2001-08-30 | Qualitas Lab | EXTRACTION OF THE CEROID FRACTION OF THE RESIN SOURCE OF AGRICULTURAL RESISTANT WINE OF CORTICA WITH SUPERCRITICAL FLUID |
DE60132184T2 (en) * | 2000-04-12 | 2009-01-15 | Liplasome Pharma A/S | LIPIDEN-BASED DRUG DISPENSING SYSTEMS AGAINST PARASITIC INFECTIONS |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
RU2004115001A (en) * | 2001-10-16 | 2005-04-10 | Аванир Фармасьютикалс (Us) | VIRUS SUPPRESSION BY N-DOCOSANOL |
DE10203688A1 (en) | 2002-01-31 | 2003-08-07 | Bayer Cropscience Ag | Synergistic insecticidal mixtures |
DE10207242A1 (en) * | 2002-02-21 | 2003-09-04 | Bayer Cropscience Ag | Synergistic insecticidal mixtures |
US7214394B2 (en) * | 2002-05-31 | 2007-05-08 | Archer-Daniels-Midland Company | Policosanol compositions, extraction from novel sources, and uses thereof |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US8119150B2 (en) * | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
EP1556009B2 (en) | 2002-10-25 | 2021-07-21 | Foamix Pharmaceuticals Ltd. | Cosmetic and pharmaceutical foam |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
CA2536482C (en) | 2003-08-25 | 2012-07-24 | Foamix Ltd. | Penetrating pharmaceutical foam |
US20050074443A1 (en) * | 2003-10-03 | 2005-04-07 | Treadwell Benjamin V. | Methods of attenuating autoimmune disease and compositions useful therefor |
CA2610662A1 (en) | 2005-05-09 | 2007-05-18 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
WO2009072007A2 (en) | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
WO2010041141A2 (en) | 2008-10-07 | 2010-04-15 | Foamix Ltd. | Oil-based foamable carriers and formulations |
CA2712120A1 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
CA2760186C (en) | 2009-04-28 | 2019-10-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
WO2011013009A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
WO2011013008A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US8871184B2 (en) | 2009-10-02 | 2014-10-28 | Foamix Ltd. | Topical tetracycline compositions |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US8470833B2 (en) | 2009-12-15 | 2013-06-25 | Mcneil-Ppc, Inc. | Hair growth and/or regrowth compositions |
US8470880B2 (en) | 2009-12-15 | 2013-06-25 | Mcneil-Ppc, Inc. | Methods of reducing hair loss and/or facilitating hair growth and/or regrowth |
WO2011112997A1 (en) | 2010-03-11 | 2011-09-15 | Chemic Laboratories, Inc. | Novel compositions and methods |
US8846725B2 (en) | 2011-01-24 | 2014-09-30 | Quadex Pharmaceuticals, Llc | Highly penetrating compositions and methods for treating pathogen-induced disordered tissues |
US9125911B2 (en) | 2013-03-14 | 2015-09-08 | Quadex Pharmaceuticals, Llc | Combined systemic and topical treatment of disordered tissues |
US9463180B2 (en) | 2013-03-14 | 2016-10-11 | Quadex Pharmaceuticals, Llc | Treatment of molluscum contagiosum |
US9549930B2 (en) | 2013-03-14 | 2017-01-24 | Quadex Pharmaceuticals, Llc | Combined systemic and topical treatment of disordered and/or prodromal stage tissue |
US9675537B2 (en) | 2014-06-30 | 2017-06-13 | Johnson & Johnson Consumer Inc. | Hair growth composition and method |
WO2017029647A1 (en) | 2015-08-20 | 2017-02-23 | Meir Eini | Tetracycline management of egfr inhibitor associated dermatoses |
US11666520B2 (en) | 2015-12-28 | 2023-06-06 | Johnson & Johnson Consumer Inc. | Hair growth composition and method |
MX2020012139A (en) | 2016-09-08 | 2021-01-29 | Vyne Pharmaceuticals Inc | Compositions and methods for treating rosacea and acne. |
EP4003302A1 (en) | 2019-07-31 | 2022-06-01 | Journey Medical Corporation | Compositions and methods and uses thereof |
US20230037905A1 (en) | 2019-12-31 | 2023-02-09 | Vyne Therapeutics Inc. | Topical composition comprising tofacitinib and fingolimod |
-
1989
- 1989-04-28 US US07/345,084 patent/US4874794A/en not_active Expired - Lifetime
-
1990
- 1990-04-16 EP EP90906552A patent/EP0428642B1/en not_active Expired - Lifetime
- 1990-04-16 JP JP2506223A patent/JPH03505882A/en active Pending
- 1990-04-16 WO PCT/US1990/002045 patent/WO1990013216A2/en active IP Right Grant
- 1990-04-16 DE DE90906552T patent/DE69003652T2/en not_active Expired - Lifetime
- 1990-04-16 AT AT90906552T patent/ATE95060T1/en active
- 1990-04-16 DK DK90906552.6T patent/DK0428642T3/en active
- 1990-04-16 ES ES90906552T patent/ES2060158T3/en not_active Expired - Lifetime
- 1990-04-16 DE DE122007000080C patent/DE122007000080I2/en active Active
-
1997
- 1997-06-26 HK HK120497A patent/HK120497A/en not_active IP Right Cessation
-
2008
- 2008-06-05 NL NL300354C patent/NL300354I2/en unknown
Also Published As
Publication number | Publication date |
---|---|
DE122007000080I2 (en) | 2008-11-06 |
ES2060158T3 (en) | 1994-11-16 |
NL300354I1 (en) | 2008-08-01 |
EP0428642B1 (en) | 1993-09-29 |
DE69003652T2 (en) | 1994-03-24 |
US4874794A (en) | 1989-10-17 |
ATE95060T1 (en) | 1993-10-15 |
JPH03505882A (en) | 1991-12-19 |
DE69003652D1 (en) | 1993-11-04 |
DE122007000080I1 (en) | 2008-02-28 |
HK120497A (en) | 1997-09-05 |
DK0428642T3 (en) | 1994-02-21 |
NL300354I2 (en) | 2008-10-01 |
EP0428642A1 (en) | 1991-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4874794A (en) | Inflammatory disease treatment | |
US5057501A (en) | Methods for treatment of papulosquamous and eczematous diseases | |
EP1392282B1 (en) | Dermatological and cosmetic compositions comprising a furfuryl derivative | |
JP3172177B2 (en) | Anti-flame mixtures derived from emu oil | |
KR100775803B1 (en) | Dermal compositions containing coenzyme q as the active ingredient | |
US20030170194A1 (en) | Pharmaceutical and/or cosmetic composition containing an organosiloxane and a phospholipid | |
US5166219A (en) | Systemic anti-inflammatory treatment | |
US5194451A (en) | Systemic anti-inflammatory treatment | |
JPS62269673A (en) | Antibacterial preserving composition | |
EP0022046A1 (en) | Drug composition based on plants and process for its preparation | |
US5219880A (en) | Treatment of viral tumors and hemorrhoids with artemisinin and derivatives | |
DE69724629T2 (en) | COMPOSITIONS AND THEIR USE | |
US20240033241A1 (en) | Composition for external use on skin for inflammatory diseases | |
JP5732471B2 (en) | Pharmaceutical composition or analogue comprising a solvent mixture and a vitamin D derivative | |
US5071879A (en) | Systemic antiviral treatment | |
US5070107A (en) | Systemic antiviral treatment | |
EP0965340B1 (en) | Dermatologic preparation | |
US4983625A (en) | Psoralene-based bath compositions for treatment of skin disorders | |
RU2233152C1 (en) | Anti-inflammatory and anti-itching cream for treatment of dermatological disease | |
FR2588474A1 (en) | SYNERGETIC ANTI-INFLAMMATORY COMPOSITIONS BASED ON A CORTICOSTEROID AND AN AGONIST BETA | |
CA1316460C (en) | Use of glycerol ether for epidermal growth | |
PT98757A (en) | PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PSORIASIS CONTAINING GAMA-LINOLIC ACID AS ACTIVE INGREDIENT | |
Schaefer et al. | Anthralin—facts, trends and unresolved problems | |
DE3712758A1 (en) | STABLE ANTI-ACNE COMPOSITION BASED ON ERYTHROMYCIN | |
EP0150638A1 (en) | Pyrethroid composition for the local treatment of skin diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1990906552 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1990906552 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1990906552 Country of ref document: EP |